European Union - Czech - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

European Union - Czech - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

European Union - Czech - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mnohočetný myelom - antineoplastická činidla - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

European Union - Czech - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulární blokáda - všechny ostatní terapeutické přípravky - zvrat neuromuskulární blokády vyvolané rocuroniem nebo vekuroniem. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

European Union - Czech - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostaty, nádorů, kastrace-odolné - antineoplastická činidla - treatment of adult patients with prostate cancer.

European Union - Czech - EMA (European Medicines Agency)

amgen technology (ireland) uc - ekulizumab - hemoglobinurie, paroxysmální - imunosupresiva - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). důkazy o klinické prospěšnosti je prokázána u pacientů s hemolýza s klinickým příznakem(s) svědčí o vysoké aktivity nemoci, bez ohledu na to, transfúze historie (viz bod 5.

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

sol s.p.a array - 3084 kyslÍk - medicinální plyn, stlačený - 100% - kyslÍk

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

sol s.p.a array - 2473 oxid dusnÝ - medicinální plyn, zkapalněný - 100% - oxid dusnÝ